AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
25min chapter
FDA advisors say no to MDMA. What’s the impact? With Josh Hardman
Business Trip
Navigating MDMA's Approval Challenges
This chapter explores the intricacies of the FDA advisory committee's recent meeting on MDMA therapy for PTSD, highlighting critical concerns over data gaps and uncompleted liver toxicity tests. It contrasts personal testimonies supporting MDMA with strong opposition, leading to an overwhelming negative vote from the committee regarding its effectiveness. The discussion also emphasizes the complexity of regulatory evaluations in psychedelic research, taking into account ethical considerations, placebo effects, and societal stigma.
00:00
Transcript
Episode notes
Get the Snipd
podcast app
Unlock the knowledge in podcasts with the podcast player of the future.
AI-powered
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode
Save any
moment
Hear something you like? Tap your headphones to save it with AI-generated key takeaways
Share
& Export
Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more
AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode